KAM
TRIL

Kazazian Asset Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Kazazian Asset Management’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-4,392
Closed -$57K – 88
2015
Q3 		$57K Buy
4,392
+350
+9% +$6.43K 0.07% 78
2015
Q2 		$88K Buy
+4,042
New +$92.1K 0.09% 65

Other funds holding TRIL

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $1.14B AUM 48.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCI
Ridgeback Capital Investments Miami Beach, Florida $560K AUM
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Kazazian Asset Management's TRIL Position: Q4 2015 in Review

Kazazian Asset Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2015, closing a stake of 4,392 shares — an estimated $57K sold.

Kazazian Asset Management first reported a position in TRIL in Q2 2015 and held it in 2 quarters. The position peaked at $88K in Q2 2015. 29 funds tracked by Wall St. Rank hold TRIL as of Q4 2015.

  • Kazazian Asset Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2015 after selling out during the quarter.
  • Kazazian Asset Management sold 4,392 Trillium Therapeutics Inc. shares in Q4 2015, an estimated $57K.
  • Kazazian Asset Management first reported a position in Trillium Therapeutics Inc. in Q2 2015 and held it in 2 quarters.
  • Kazazian Asset Management's Trillium Therapeutics Inc. position peaked at $88K in Q2 2015.
  • 29 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2015.

Based on Kazazian Asset Management's 13F filing for Q4 2015, filed 16 Feb 2016.